BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, ...
The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...
The FDA cleared an investigational new drug application to advance NOV05 in a phase 2 clinical trial in noninfectious ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 ...
PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage ...
The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...
A New Approach Enabling Physicians to Treat Toenail Fungus at the Point-of-Care HSG 42 is highly differentiated. It is ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ...
“Let it grow, let it blossom,” said Eric Clapton, and so the Food and Drug Administration expects of expanded access programs with the issuance of its guidance on “Expanded Access to Investigational ...
The U.S. Food and Drug Administration (FDA) has issued updated guidance on Expanded Access to Investigational Drugs for Treatment Use, clarifying how drug developers, physicians, and patients can ...
The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results